Since the 1990s, there has been a progressive liberalization of prohibition policy, which has gained momentum over the last decade. The facts tell their own tale: The count of people worldwide who have free access to cannabis as a stimulant has tenfolded from around 12 million to over 120 million in the past 7 years. In many countries, including 13 EU countries, cannabis has been re-approved as a marketable drug and can be obtained by prescription from pharmacies. The USA and Canada played a pioneering role in the legalization process. In Canada, as well as in 10 member states of the USA, the use of cannabis as a stimulant has already been fully legalized. End of 2018, Luxembourg was the first EU country to announce full legalization.


Growing Industry

Economic experts today describe the cannabis business as one of the fastest growing industries in the world. Global sales of cannabis and products containing cannabinoids are expected to grow from approximately $18 billion € today to more than $150 billion € by 2028, according to latest studies. The latest developments leave little doubt about these forecasts.

Statistical facts Europe



743 million


total expenditure

healthcare sector

2.300 Billion. €


average price

per gram Cannabis

8,33 €


Expected market volume

Medical cannabis 2028

58 billion €


Estimated legal cannabis market 2028

65 billion €


Current number of cannabis users

89 million


Expected total cannabis market by 2028

128 billion €


Total value of gross domestic product

16.6 Billion.

Europe with potential

In Germany and Switzerland alone, an estimated 310.000 Kilograms of cannabis with a Market Value of 2,5 Billion € are consumed annually. Since March 2017, cannabis in the form of flowers and extracts has again been approved as a marketable drug in Germany and can be obtained by prescription from pharmacies. Due to the rapid pace of approval as a stimulant in the USA and Canada, many companies produce on a large scale over there. In Europe, on the other hand, cannabis is currently only produced in the Netherlands to a significant extent.

Domestic Production
instead of Imports

Demand in Europe is almost exclusively met by imports from Canada and the Netherlands. The pharmacies are reporting latent bottlenecks in the supply of patients receiving medical cannabis on prescription. In Germany, licences are currently being granted for the cultivation of medical cannabis with a psychotropic THC content, which is currently limited to a total quantity of only 10.4 tonnes within 4 years. This is far from sufficient to meet the demand and far from interesting for a commercial grower.

Domestic Production
instead of Imports